#pharma stocks

3개의 글

May 11, 2026

GILD Gilead Sciences Stock Outlook 2026: Yeztugo Launch Rewrites the HIV Playbook

Gilead Sciences (GILD) stock outlook 2026: Biktarvy $3.4B quarterly, Yeztugo $166M debut, anito-cel CAR-T PDUFA Dec 23, 2026, 2.46% dividend yield, analyst target $152. Full pipeline, risks, and 3 price scenarios for US investors.

GILD Gilead HIV

May 11, 2026

AZN AstraZeneca Stock Outlook 2026: Can the ADC Empire Sustain Its Momentum?

AstraZeneca (AZN) 2026 stock outlook covering Tagrisso, Enhertu, Datroway ADC pipeline, Farxiga CVRM growth, China VBP risk, and US Medicare price negotiation impact. Revenue data through Q1 2026.

AZN AstraZeneca biotech

May 8, 2026

ABBV AbbVie Stock Outlook 2026: Skyrizi and Rinvoq Prove the Humira Replacement Was Real

AbbVie (ABBV) stock outlook 2026. Humira biosimilar erosion absorbed, Skyrizi+Rinvoq now exceeding peak Humira combined, 3.41% dividend yield, 12-month price target scenarios analyzed.

ABBV AbbVie dividend aristocrat